Implanted Standby Defibrillators
To The Editor:
I am concerned about the implications of the Editorial by Drs. Lown and Axelrod which appeared in the October 1972 issue of Circulation. Although the authors rightfully point out the numerous technical problems still to be overcome in the development of such defibrillators, their conclusions in the last three paragraphs indicate a heavy bias in favor of "practical research." Although Dr. Lown has been eminently successful with this approach, I believe he is unjustified in using this yardstick to evaluate the research activities of others. The authors take Drs. Mirowski et al. to task for a 1970 article in which they state: "It is too early to determine exactly the indications and contraindications of the standby automatic defibrillator." Drs. Lown and Axelrod believe such a statement should be answered before social energies are expended on research and development of such a device.
Since when have answers to such questions been required before research is undertaken? Are Drs. Lown and Axelrod so clairvoyant that they can see the ultimate impractability of someone else's research energies thereby prematurely labelling that work "an imperfect solution in search of a plausible and practical application."? Fortunately, sincere investigators will continue to attack problems even when the prospect of solution is slight and when sensible people shake their heads.
ARTHUR J. Moss, M.D. University of Rochester School of Medicine and Dentistry Rochester, New York
To the Editor:
We appreciate the editorial focus afforded by Circulation' to our transvenous automatic defibrillator concept.2 3 In this Editorial, Drs. Lown and Axelrod raise a series of objections and emphasize the difficulties in implementing such an approach. While these admittedly great difficulties have not escaped our attention, the potential advantages, overlooked by the authors, amply justified the energies expended to explore this uncharted area.
Interestingly enough, after an intensive search for the real and hypothetic difficulties, Drs. Lown and Axelrod recognize that the technologic problems are subject to solutions. However, some of their assumptions are simply unwarranted. An example is the statement that energies required for catheter defibrillation in man would necessarily be higher than those in dogs. In fact, preliminary clinical results compare favorably to animal data, and this even under Circulation, Volume XLVII, May 1973 conditions of extreme ischemia.4 5 As far as endomyocardial effects of catheter electroshock are concerned, the lesions, when present, are small, localized, and of little significance in view of the otherwise fatal outcome of the arrhythmia. Fortunately, Dr. Lown's findings of myocardial damage due to transthoracic DC electro-shock6 have not led to the abandonment of this technic by the medical profession.
In contrast to Drs. Lown and Axelrod, we do not foresee difficulties in identifying populations at particularly high risk of dying from ventricular fibrillation. The implantation of the transvenous automatic defibrillator in these patients may not necessarily be more "burdening" (using the authors' expression) than drug therapy. In fact, at this time we are aware of no effective long-term antiarrhythmic regimen capable of reducing the present prohibitive toll of sudden coronary deaths.
The authors' overcautious and negative attitude to the approach under investigation seems certainly premature at this experimental prototype stage. Would it not be more appropriate to postpone disqualification of this new way of approaching a major cause of mortality, however imperfect it may seem to be, until it faces the test of clinical trials?
Regrettably, almost three decades elapsed between the development of the first experimental model of the artificial cardiac pacemaker7 and its clinical acceptance. After an additional decade or more of extensive experience and continuous technologic advances, the pacemaker still remains a rather imperfect and occasionally a harmful device. Nevertheless, its rewardrisk ratio has been sufficiently high to warrant its use. We are confident that much less time will be required to develop the transvenous automatic defibrillator, to bring it to an attractive reward-risk level, and, finally, to
